- Home
- NA vs CRDL Comparison
NA vs CRDL Comparison
Compare NA & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NA
- CRDL
- Stock Information
- Founded
- NA 2019
- CRDL 2017
- Country
- NA China
- CRDL Canada
- Employees
- NA N/A
- CRDL N/A
- Industry
- NA Semiconductors
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NA Technology
- CRDL Health Care
- Exchange
- NA Nasdaq
- CRDL Nasdaq
- Market Cap
- NA 95.7M
- CRDL 90.4M
- IPO Year
- NA 2022
- CRDL N/A
- Fundamental
- Price
- NA $4.77
- CRDL $1.17
- Analyst Decision
- NA
- CRDL Strong Buy
- Analyst Count
- NA 0
- CRDL 2
- Target Price
- NA N/A
- CRDL $9.00
- AVG Volume (30 Days)
- NA 115.9K
- CRDL 835.2K
- Earning Date
- NA 08-15-2025
- CRDL 11-13-2025
- Dividend Yield
- NA N/A
- CRDL N/A
- EPS Growth
- NA N/A
- CRDL N/A
- EPS
- NA N/A
- CRDL N/A
- Revenue
- NA $3,369,693.00
- CRDL N/A
- Revenue This Year
- NA N/A
- CRDL N/A
- Revenue Next Year
- NA N/A
- CRDL N/A
- P/E Ratio
- NA N/A
- CRDL N/A
- Revenue Growth
- NA N/A
- CRDL N/A
- 52 Week Low
- NA $2.77
- CRDL $0.77
- 52 Week High
- NA $31.48
- CRDL $2.24
- Technical
- Relative Strength Index (RSI)
- NA 39.49
- CRDL 56.34
- Support Level
- NA $4.61
- CRDL $1.14
- Resistance Level
- NA $5.97
- CRDL $1.38
- Average True Range (ATR)
- NA 0.36
- CRDL 0.08
- MACD
- NA -0.07
- CRDL 0.02
- Stochastic Oscillator
- NA 11.76
- CRDL 45.67
About NA Nano Labs Ltd
Nano Labs Ltd operates as a fabless IC design company and product solution provider in China. It engages in the development of HTC chips, HPC chips, distributed computing and storage solutions, smart-NICs, vision computing chips, and distributed rendering. Its products comprise Cuckoo 1.0 Chip, Cuckoo 2.0 Chip, and Darkbird 1.0 Chip. Majority of the company revenue comes from China.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.